KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EBT (2019 - 2025)

Royalty Pharma (RPRX) has disclosed EBT for 7 consecutive years, with $355.9 million as the latest value for Q4 2025.

  • Quarterly EBT rose 6.45% to $355.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, changed 0.5% year-over-year, with the annual reading at $1.3 billion for FY2025, 0.5% changed from the prior year.
  • EBT hit $355.9 million in Q4 2025 for Royalty Pharma, down from $444.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $806.8 million in Q2 2021 to a low of -$610.0 million in Q4 2022.
  • Historically, EBT has averaged $291.3 million across 5 years, with a median of $278.1 million in 2021.
  • Biggest five-year swings in EBT: plummeted 1236.61% in 2022 and later soared 10243.53% in 2025.
  • Year by year, EBT stood at $53.7 million in 2021, then tumbled by 1236.61% to -$610.0 million in 2022, then soared by 217.63% to $717.6 million in 2023, then plummeted by 53.41% to $334.4 million in 2024, then grew by 6.45% to $355.9 million in 2025.
  • Business Quant data shows EBT for RPRX at $355.9 million in Q4 2025, $444.2 million in Q3 2025, and $90.6 million in Q2 2025.